Pricing
  1. JP-listed companies
  2. Linical Co., Ltd.
  3. Financials
  4. Return on Assets

Linical Co., Ltd.【JP:2183】

Market cap
¥6.9B
P/E ratio
-3.7x
Linical helps pharmaceutical companies develop and launch new drugs by providing clinical trial services, post-market safety monitoring, and drug discovery support.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndReturn on Assets (Million JPY)YoY (%)
Mar 31, 2025-3-262.23%
Mar 31, 20241.9-68.93%
Mar 31, 20236.1+18.63%
Mar 31, 20225.1+39.34%
Mar 31, 20213.7+4.27%
Mar 31, 20203.5-30.50%
Mar 31, 20195.1-65.81%
Mar 31, 201814.8-21.31%
Mar 31, 201718.8-9.98%
Mar 31, 201620.9

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)